News Release


Taiho Pharmaceutical to Launch Tiovita Drink Aibitasu Zero Nationwide on May 28, 2018 "No fatigue the next day!" (28/05/2018)

Taiho Pharmaceutical Co., Ltd. announced today that it has launched Tiovita Drink Aibitasu Zero ( third-class OTC drug), the first caffeine-free, sugar-free product in the Tiovita series, throughout Japan on Monday, May 28, 2018.

The new product retains the features of the original Tiovita Drink Aibitasu* but without the caffeine and sugar, resulting in a low calorie product at only 7 kcal per bottle. As the first caffeine-free product in the Tiovita series, Tiovita Drink Aibitasu Zero is a nutritious drink that can be enjoyed before bedtime.

Taiho Pharmaceutical is determined to keep contributing to healthy living by providing Tiovita series products.

*Tiovita Drink Aibitasu has a smooth blueberry flavor and contains 1,000 mg of taurine and more Vitamin B1, B2, and B6 than Tiovita Drink (a designated quasi-drug).

Features of Tiovita Drink Aibitasu Zero

  • First caffeine-free, sugar-free product in the Tiovita series
  • Low calories: 7 kcal per bottle
  • 1,000 mg of taurine, which is an active ingredient, and more Vitamin B1, B2, and B6 compared to Tiovita Drink (a designated quasi-drug)
  • Smooth blueberry flavor

Product Overview

Brand name Tiovita Drink Aibitasu Zero
Risk categories Third-class OTC drug
Suggested retail price 180 yen (excl. tax) per bottle
Ingredients Per 100 mL bottle
Taurine 1000 mg
Inositol 50 mg
Niacinamide 20mg
Thiamine nitrate (Vitamin B1) 10 mg
Riboflavin sodium phosphate (Vitamin B2) 15 mg
Pyridoxine hydrochloride (Vitamin B6) 50 mg
Carnitine chloride 120 mg
Indications ・Nutritional fortification
・Weak constitution improvement
・Nutritional support for physical exhaustion, during and after illness, loss of appetite, malnutrition, febrile debilitating illness, before and after childbirth, etc.
Dosage and administration For adults (15 years and older): 1 bottle (100 mL) per day
Launch date Nationwide on Monday, May 28, 2018

Information in this news release was current as of the original release date.

<< Back